drugset / Trial / NCT04665947
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I, first-in-human study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).
Timeline
- Start
- 2020-12-18
- Primary completion
- 2027-07-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [177Lu]Lu DOTA-ABM-5G | Unknown | 25 mbq | — |
| Subject | [177Lu]Lu DOTA-ABM-5G | Unknown | 200 mbq | — |
| Subject | [68Ga]Ga DOTA-5G | Diagnostic / imaging agent | — | — |